MaxCyte (MXCT) Corporate presentation summary

Business overview and market opportunity

• Provides scalable cell engineering solutions for cell and gene therapy, supporting 13 clinical and commercial therapies as of December 2025.

• Addresses genetic diseases, solid tumors, infectious diseases, hematological malignancies, and autoimmune diseases.

• Ex-vivo cell and gene therapy market includes 201 biotechs and hundreds of programs across research, pre-clinical, clinical, and commercial stages.

• Supported by a robust IP portfolio with over 200 granted patents and 100+ pending worldwide.

• Industry is rapidly growing, with $11.1B raised in 2025 and 48 approved cell and gene therapies globally.

Technology and platform

• Expert™ platform enables non-viral cell engineering with high transfection efficiency and scalability up to 200 billion cells.

• Flow Electroporation® technology integrates into closed cGMP workflows, supporting a wide range of cell types and gene editing tools.

• Platform supports multiplex and sequential engineering, overcoming payload limitations of viral approaches.

• Over 100 optimized protocols developed over 25 years, with FDA Master File support for regulatory filings.

• Additional applications include drug discovery, viral vector production, antibody/protein production, and vaccine development.

Business model and customer relationships

• Generates recurring revenue through instrument sales, single-use disposables, annual license fees, and milestone/royalty payments.

• Strategic Platform License (SPL) agreements provide significant milestone and royalty potential, with 31 SPL agreements and 12 active clinical programs.

• SPL economics include multi-phase milestones, royalties, and recurring instrument/disposable sales.

• Customer base includes leading global cell therapy developers, academic centers, and pharma/biotech companies.

• Field Application Scientists provide scientific, technical, and regulatory support to optimize customer processes.